A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis
NCT ID: NCT00458146
Last Updated: 2008-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
100 participants
INTERVENTIONAL
2007-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
MM-093
MM-093
60mg MM-093/week as a subcutaneous injection for 3 months
2
Placebo
MM-093
60mg MM-093/week as a subcutaneous injection for 3 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MM-093
60mg MM-093/week as a subcutaneous injection for 3 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have active RA consisting of \> or equal to 6 tender joints and \> or equal to 6 swollen joints and one of the following:CRP or ESR levels of ULN
* Have an ACR functional class of I-III.
* Have had RA for at least 6 months.
* Had disease onset at \> 16 years of age.
* Aged 18 - 80 years.
* Currently being treated with a stable, well tolerated weekly dose of MTX between 10-25 mg for at least 6 consecutive prior to screening visit.
* Currently being treated with folic/folinic acid in conjunction with their MTX treatment.
(Note: Patients may begin folic/folinic acid treatment after their screening visit, but must remain on stable dose for two weeks before undergoing the Day 1 assessments.)
* Willing to remain on a constant, weekly dose of MTX and folic/folinic acid through out the duration of the study.
* Understand, sign, and date the written, voluntary informed consent form at the screening visit prior to any protocol - specific procedures being performed.
* Be able and willing to comply with study visits and procedures per protocol.
* Women of childbearing potential must use a medically acceptable means of birth control in an effective manner and agree to continue its use during the study and for 4 weeks after the last dose of study drug. Women who have had a complete surgical hysterectomy or are postmenopausal (absence of menstrual period for at least one year or \> 52 years old) are exempt from this requirement. Medically acceptable forms of birth control include oral contraceptives, injectable or implantable methods, intrauterine devices, tubal ligation (if performed more than 1 year before screening), or properly used barrier contraception. Additionally, the use of condoms is suggested as an adjunct to the methods previously addressed to protect against sexually transmitted diseases and to provide additional protection against accidental pregnancy.
* Sexually active men must agree to use a medically acceptable form of contraception during the study and continue for 4 weeks after the last dose of study drug.
* Able to store patient kit/cooler containing drug in a refrigerator at home.
Exclusion Criteria
1. Any B - cell or antibody depleting therapy , including plasmaphoresis or Prosorba columns (6 months)
2. Leflunomide, Adalimumab (Humira)(3 months)
3. Investigational biologics (2 months)
4. Infliximab (Remicade) (2 months)
5. Cyclosporine, sulphasalazine, auranofin, intramuscular gold, azathioprine, D-penicillamine, tacrolimus (6 weeks)
6. Investigational small molecules (e.g. NSAIDS or Cox-2 inhibitors)(4 weeks)
7. Use more than 10mg/day of prednisone or equivalent (4 weeks)
8. Bolus intramuscular/intravenous (IM/IV) treatment with corticosteroids (\>20 mg prednisone or equivalent)(4 weeks)
9. Intra-articular corticosteroid injection (4 weeks)
10. Etanercept (Enbrel) (4 weeks)
11. Anakinra (Kineret) (2 weeks)
12. Use of more than one NSAID (current)
13. Dose of NSAID greater than maximum recommended dose in the product information (current)
* Significant concurrent medical diseases including:
1. Cancer, or a history of cancer (other than successfully resected cutaneous basal and squamous cell carcinoma) within 5 years before the screening visit.
2. Any condition for which participation in this study is judged by the physician to be detrimental to the patient, such as history of significant or unstable cardiac, pulmonary, gastrointestinal, neurological, or psychiatric disease, or a DMARD-related severe, potentially life threatening AE.
3. Significant ongoing infection requiring systemic antibiotic, antifungal, antiviral, or anti-myobacterial therapy.
* Autoimmune or connective tissue disorder other than rheumatoid arthritis (e.g. Systemic Lupus Erythematosis, Scleroderma, or Psoriatic Arthritis)
* Grade 2 or above leukopenia (i.e. white blood cells \< 3000/mm\^3 \[SI units: \< 3.0 x 10\^9/L)
* Thrombocytopenia or thrombocytosis (platelets \> 125,000/mm\^3 or \> 1,000,000/mm\^3 \[SI units: \< 125 x 10\^9/L or \> 1,000 x 10\^9/L\]), respectively.
* Grade 2 or above liver function abnormality(i.e. total bilirubin .1.5 x the upper limit of normal; or aspartate aminotransfersate \[AST/SGOT\] or alanine aminotransferase \[ALT/SGPT\]\> 2.5 x upper limit of normal.
* Renal disease (including serum creatinine level \> 1.5 x the upper limit of normal).
* Any history of immunodeficiency syndromes or infection with human immunodeficiency virus (HIV), or a history of hepatitis C or chronic hepatitis B.
* Pregnant or breastfeeding women or women planning to become pregnant during the study or within 4 weeks after the last dose of study drug.
* Any major surgery, including joint surgery, within 3 months before the screening visit.
* Scheduled elective surgery during the study participation.
* Participated in any previous clinical trial using MM-093 or have any prior exposure to MM-093.
* History of severe hypersensitivity to goat, sheep, or cow milk. (Patients who are lactose intolerant are not excluded).
* Any other condition that the investigator feels would jeopardize the integrity of the study (e.g. a CTCAE grade 2 or above clinical finding or laboratory result).
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merrimack Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Merrimack Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Montgomery Rheumatology Associates
Montgomery, Alabama, United States
East Valley Rheumatology & Osteoporosis
Gilbert, Arizona, United States
Radiant Research
Scottsdale, Arizona, United States
Arthritis Medical Center of the Central Coast
Santa Maria, California, United States
National Jewish Medical and Research Center
Denver, Colorado, United States
Denver Arthritis Clinic
Denver, Colorado, United States
New England Research Associates
Trumbull, Connecticut, United States
Arthritis and Rheumatic Disease Specialties
Aventura, Florida, United States
Paddock Park Clinical Research
Ocala, Florida, United States
Arthritis Research of Florida, Inc.
Palm Harbor, Florida, United States
Sarasota Arthritis Research Center
Sarasota, Florida, United States
Illinois Bone & Joint Institute
Morton Grove, Illinois, United States
Wichita Clinic
Wichita, Kansas, United States
Arthritis Center of Nebraska
Lincoln, Nebraska, United States
Arthritis Center of Reno
Reno, Nevada, United States
Arthritis Center and Carolina Bone and Joint
Charlotte, North Carolina, United States
East Pennsylvania Rheumatology Association
Bethlehem, Pennsylvania, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
Rheumatology and Internal Medicine
Amarillo, Texas, United States
University of Utah Division of Rheumatology
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MM-093-01-201
Identifier Type: -
Identifier Source: org_study_id